


Defining unique clinical hallmarks for immuno-oncology–based therapies



Authors

Olivier Michielin, Aly-Khan A. Lalani, Caroline Robert, Padmanee Sharma, Solange Peters

Correspondence

Olivier.Michielin@chuv.ch

In brief

I-O therapies provide unique hallmarks associated with significantly improved clinical outcomes and a distinct, immune-based safety profile. OS remains the gold standard endpoint; however, investigation of measures inclusive of and beyond long-term survival have evolved, which lead to a greater appreciation of the effectiveness of I-O therapies